NASDAQ:OCS Oculis (OCS) Stock Price, News & Analysis $11.62 +0.18 (+1.57%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$11.50▼$11.7050-Day Range$11.01▼$12.0052-Week Range$9.05▼$14.50Volume5,933 shsAverage Volume33,716 shsMarket Capitalization$470.81 millionP/E RatioN/ADividend YieldN/APrice Target$30.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Oculis alerts: Email Address Oculis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside159.5% Upside$30.17 Price TargetShort InterestHealthy0.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.92) to ($2.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.98 out of 5 starsMedical Sector645th out of 936 stocksPharmaceutical Preparations Industry298th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingOculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOculis has only been the subject of 4 research reports in the past 90 days.Read more about Oculis' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.08% of the float of Oculis has been sold short.Short Interest Ratio / Days to CoverOculis has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oculis has recently decreased by 13.88%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOculis does not currently pay a dividend.Dividend GrowthOculis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCS. Previous Next 2.0 News and Social Media Coverage News SentimentOculis has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Oculis this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oculis insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 22.30% of the stock of Oculis is held by institutions.Read more about Oculis' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Oculis are expected to decrease in the coming year, from ($1.92) to ($2.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oculis is -6.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oculis is -6.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOculis has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oculis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. About Oculis Stock (NASDAQ:OCS)Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Read More OCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCS Stock News HeadlinesJuly 25 at 9:54 AM | msn.comOculis’ (OCS) Stock Moves Sideways Amid Growing AnticipationJuly 21, 2024 | americanbankingnews.comOculis Holding AG (NASDAQ:OCS) Receives $30.17 Average PT from AnalystsJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 19, 2024 | nz.finance.yahoo.comOculis Holding AG (CR5.SG)June 27, 2024 | globenewswire.comOculis and EURETINA Announces the Ramin Tadayoni AwardJune 10, 2024 | globenewswire.comOculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine StrategyJune 10, 2024 | globenewswire.comOculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine StrategyJune 4, 2024 | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 30, 2024 | globenewswire.comOculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory BoardMay 30, 2024 | globenewswire.comOculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory BoardMay 23, 2024 | finance.yahoo.comWhile institutions own 39% of Oculis Holding AG (NASDAQ:OCS), individual investors are its largest shareholders with 55% ownershipMay 18, 2024 | msn.comOCS Stock Earnings: Oculis Holding Misses EPS, Misses Revenue for Q1 2024May 17, 2024 | globenewswire.comOculis updates share capital for its existing at-the-market offering programMay 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Oculis Holding (OCS)May 8, 2024 | markets.businessinsider.comOculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic NeuritisMay 8, 2024 | globenewswire.comOculis Reports Q1 2024 Financial Results and Provides Company UpdatesMay 8, 2024 | globenewswire.comOculis Reports Q1 2024 Financial Results and Provides Company UpdatesSee More Headlines Receive OCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/27/2024Next Earnings (Estimated)9/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCS CUSIPN/A CIK1953530 Webwww.oculis.com Phone41-21-711-3970FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$30.17 High Stock Price Target$37.00 Low Stock Price Target$20.00 Potential Upside/Downside+159.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,920,000.00 Net Margins-6,712.02% Pretax Margin-10,040.34% Return on Equity-52.72% Return on Assets-43.72% Debt Debt-to-Equity Ratio0.01 Current Ratio4.71 Quick Ratio4.71 Sales & Book Value Annual Sales$980,000.00 Price / Sales480.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book4.05Miscellaneous Outstanding Shares40,500,000Free FloatN/AMarket Cap$470.81 million OptionableNot Optionable Beta0.28 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Riad Sherif M.B.A. (Age 56)M.D., CEO & Director Ms. Sylvia Cheung (Age 49)Chief Financial Officer Dr. Ramin Tadayoni M.D.Ph.D., Chief Scientific OfficerMs. Virginia R. Dean (Age 57)Chief Human Resources Officer Dr. Bastian Dehmel M.D. (Age 53)Chief Development Officer Mr. Páll Ragnar Jóhannesson (Age 42)Chief Business Officer Ms. Rebecca WeilChief Commercial OfficerDr. Snehal Shah Pharm.D.President of Research & DevelopmentMore ExecutivesKey CompetitorsVera TherapeuticsNASDAQ:VERAMirum PharmaceuticalsNASDAQ:MIRMZai LabNASDAQ:ZLABAkero TherapeuticsNASDAQ:AKROVerona PharmaNASDAQ:VRNAView All CompetitorsInstitutional OwnershipNan Fung Group Holdings LtdSold 82,555 shares on 5/14/2024Ownership: 1.077%View All Institutional Transactions OCS Stock Analysis - Frequently Asked Questions How have OCS shares performed this year? Oculis' stock was trading at $11.23 on January 1st, 2024. Since then, OCS shares have increased by 3.5% and is now trading at $11.6250. View the best growth stocks for 2024 here. How were Oculis' earnings last quarter? Oculis Holding AG (NASDAQ:OCS) posted its earnings results on Wednesday, May, 8th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.03. The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.28 million. Oculis had a negative trailing twelve-month return on equity of 52.72% and a negative net margin of 6,712.02%. How do I buy shares of Oculis? Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCS Stock Alerts